AU2020368759A1 - Diabetes therapy targeting abnormal stem cells - Google Patents

Diabetes therapy targeting abnormal stem cells Download PDF

Info

Publication number
AU2020368759A1
AU2020368759A1 AU2020368759A AU2020368759A AU2020368759A1 AU 2020368759 A1 AU2020368759 A1 AU 2020368759A1 AU 2020368759 A AU2020368759 A AU 2020368759A AU 2020368759 A AU2020368759 A AU 2020368759A AU 2020368759 A1 AU2020368759 A1 AU 2020368759A1
Authority
AU
Australia
Prior art keywords
abnormal
diabetes mellitus
cells
cell
stem cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020368759A
Other languages
English (en)
Inventor
Miwako KATAGI
Hideto Kojima
Tomoya Terashima
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biozipcode Inc
Original Assignee
Biozipcode Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biozipcode Inc filed Critical Biozipcode Inc
Publication of AU2020368759A1 publication Critical patent/AU2020368759A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2836—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD106
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2020368759A 2019-10-18 2020-10-16 Diabetes therapy targeting abnormal stem cells Pending AU2020368759A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019191363 2019-10-18
JP2019-191363 2019-10-18
PCT/JP2020/039044 WO2021075535A1 (ja) 2019-10-18 2020-10-16 異常幹細胞を標的とする糖尿病治療

Publications (1)

Publication Number Publication Date
AU2020368759A1 true AU2020368759A1 (en) 2022-05-19

Family

ID=75538122

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020368759A Pending AU2020368759A1 (en) 2019-10-18 2020-10-16 Diabetes therapy targeting abnormal stem cells

Country Status (7)

Country Link
US (1) US20230025003A1 (https=)
EP (1) EP4035679A4 (https=)
JP (2) JPWO2021075535A1 (https=)
KR (1) KR20220103111A (https=)
CN (1) CN114828891A (https=)
AU (1) AU2020368759A1 (https=)
WO (1) WO2021075535A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0671936A1 (en) * 1992-10-15 1995-09-20 Dana-Farber Cancer Institute, Inc. TREATMENT OF INSULIN RESISTANCE IN OBESITY LINKED TYPE II DIABETES USING ANTAGONISTS TO TNF-$g(a) FUNCTION
US20040219142A1 (en) * 2002-07-19 2004-11-04 Abbott Laboratories S.A. Treatment of skin and nail disorders using TNFalpha inhibitors
WO2005045044A2 (en) * 2003-11-07 2005-05-19 Novartis Ag Use of fibroblast growth factor fragments
RU2446796C2 (ru) * 2006-12-26 2012-04-10 Фармасайкликс, Инк. Способ использования ингибиторов гистондеацетилазы и мониторинга биомаркеров в комбинированной терапии
WO2010053316A2 (en) * 2008-11-06 2010-05-14 Snu R&Db Foundation New use of sixth immunoglobulin-like domain of vcam-1
WO2011049412A2 (en) * 2009-10-23 2011-04-28 Hanwha Chemical Corporation Human recombinant monoclonal antibody that specifically binds to vcam-1 and inhibits adhesion and transmigration between leukocytes and endothelial cells
CN105640944A (zh) * 2014-12-02 2016-06-08 杨美宁 一种降低2型糖尿病合并冠心病患者sVCAM-1的方法
US10465003B2 (en) * 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
JP2019191363A (ja) 2018-04-25 2019-10-31 京セラドキュメントソリューションズ株式会社 定着装置及び画像形成装置

Also Published As

Publication number Publication date
CN114828891A (zh) 2022-07-29
JPWO2021075535A1 (https=) 2021-04-22
WO2021075535A1 (ja) 2021-04-22
KR20220103111A (ko) 2022-07-21
JP2025157483A (ja) 2025-10-15
EP4035679A4 (en) 2024-08-07
EP4035679A1 (en) 2022-08-03
US20230025003A1 (en) 2023-01-26

Similar Documents

Publication Publication Date Title
JP6254125B2 (ja) 蛋白尿腎疾患の病因における可溶性ｕＰＡＲの役割
JP2023139101A (ja) 幹細胞遊走剤を使用した糖尿病治療
US20240139129A1 (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
JP2015508155A (ja) 膵臓β細胞障害における可溶性ＭＡＮＦ
US20230025003A1 (en) Diabetes therapy targeting abnormal stem cells
JP6854515B2 (ja) 解糖系代謝制御物質のスクリーニング方法及び解糖系代謝制御剤
HK40073790A (en) Diabetes therapy targeting abnormal stem cells
Sonner et al. A GDF-15–GFRAL axis controls autoimmune T cell responses during neuroinflammation
TW200831898A (en) Treatment of insulin resistance
Sheng et al. Cyclophilin J limits linear ubiquitin signaling and controls colorectal cancer progression
HK40105070A (en) Novel method and agent for treating, diagnosing and detecting diabetes and complications
HK40074315A (en) Therapy for diabetes using stem cell migration agent
HK40073293A (en) Diabetes therapy targeting abnormal stem cells
EP4424327A1 (en) Method or agent with hdac regulator, for treatment of diabetes and complications
HK40073547A (en) Therapy for diabetes using stem cell migration agent
JP5830329B2 (ja) 腎障害の新規マーカー
Cao et al. Reactivation of Mthfd2 during heart failure drives cardiac remodeling
Shen et al. Aerobic exercise improves ventricular remodeling by promoting macrophages to phagocytose dying cardiomyocytes in heart failure model
JPWO2003063907A1 (ja) サーカディアンリズム障害改善剤
CN121494954A (zh) 靶向slc22a6的多肽、抗体、组合物及其在治疗和诊断动脉粥样硬化中的应用
CN116615241A (zh) 用于糖尿病治疗和β细胞再生的方法和组合物
Metze Darier disease
WO2015174441A1 (ja) 糖尿病の予防または治療剤のスクリーニング方法